CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma ModelSuet Ling Felce(John Radcliffe Hospital), Alison H. Banham(University of Oxford)Frontiers in OncologyApril 3, 202010.3389/fonc.2020.00448Cited by 39SaveCiteExport RISWatch citationsRelated PapersFOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas|Leukemia|2015|67